Dermatologist Interview Questions
& Model Answers, 2026

Excisional biopsy with narrow margins including the full depth wherever feasible, because Breslow thickness determines staging, sentinel node decisions and definitive margins, and a partial shave that transects the base makes accurate staging impossible. Where excision is impractical — a large facial or acral lesion — take a broad deep shave or a punch of the most atypical area guided by dermoscopy and say so explicitly on the requisition. Orient and document the specimen and photograph the site.

Use it as a structured second step after the naked-eye assessment: assess symmetry of structures and colours, network pattern and its regularity, and specific melanoma-associated features such as atypical network, irregular streaks, blue-white veil, regression structures and atypical vessels. Use the ugly duckling comparison across the patient's own lesions and sequential imaging for equivocal lesions in high-risk patients. Say when dermoscopy would not stop you biopsying, which is any lesion with a concerning history.

Match the mechanism to the phenotype and comorbidity: psoriatic arthritis, inflammatory bowel disease, cardiovascular and metabolic disease, and infection risk all steer the choice between tumour necrosis factor, interleukin-17 and interleukin-23 targeting agents. Screen for latent tuberculosis and hepatitis before starting, update vaccinations including avoiding live vaccines, and set the monitoring and reassessment schedule with a defined response target. Say what you do when a patient loses response.

Look for the severe cutaneous adverse reaction features first: mucosal involvement, skin pain, blistering and a positive Nikolsky sign, facial oedema, fever, lymphadenopathy and eosinophilia. Take a full drug timeline including new agents in the preceding weeks, examine every surface including mucosae, biopsy including a frozen section where the diagnosis is urgent, and check bloods for organ involvement. Stop the culprit drug, escalate care level, and involve the appropriate specialties. Do not treat a blistering unwell patient as an outpatient eczema flare.

Use the accepted appropriate use criteria: anatomical location in the high-risk central face, ears, genitalia and digits; aggressive histological subtypes; recurrent tumours; poorly defined borders; large size for the site; immunosuppressed patients; and tumours in previously irradiated skin. Otherwise standard excision with appropriate margins or, in selected superficial tumours, destructive or topical options. Say why margin-sparing matters functionally and cosmetically rather than treating Mohs as a default.

Confirm the indication after adequate conventional therapy or with scarring, counsel thoroughly on teratogenicity and the pregnancy prevention programme requirements including two forms of contraception and the required testing schedule, register per the applicable programme, baseline and interval lipids and liver enzymes, and discuss mood changes, dryness and photosensitivity with a plan for review. Set the cumulative dose target and the relapse expectation honestly.

Do not simply accept or simply dismiss it. Call the dermatopathologist and discuss the case with the clinical context and the photograph, request deeper levels or additional stains, consider whether the sample was representative, and re-biopsy if the discordance persists. Document the conversation. A benign report on a lesion you believe is melanoma is the single highest-risk situation in dermatology and re-biopsy is usually the right response.

Describe the case, how it was identified, the disclosure, and the process change — photography, recall systems, biopsy threshold, pathology follow-up. Dermatology's main litigation exposure is delayed melanoma diagnosis, and panels want a candidate who has systems rather than confidence.

Be honest about what you want to do and what you have done. Practices differ enormously and a mismatch here is the commonest reason dermatology hires fail within a year. Describe how you would protect medical access if the practice is cosmetically weighted.

Severe atopic dermatitis, hidradenitis or refractory psoriasis: describe reassessing the diagnosis, adherence, trigger and comorbidity management, escalation of therapy, and the psychosocial support you arranged. Chronic skin disease carries a heavy quality-of-life burden that panels expect you to name.

Teledermatology triage, education sessions, a lesion pathway with photography, or clear referral criteria: describe what you built and the effect on waiting time. Dermatology access is a widespread problem and groups value candidates who address it.

Anchor on the specialty series: dermatologists have a BLS OEWS May 2025 median of $328,730 a year with the top 10% above $578,560. Then say the figure depends heavily on the mix of medical, surgical and cosmetic work, whether the practice is private or employed, and the payer mix, and ask for the group's production data before naming a number.

Ask explicitly whether you participate in cosmetic procedure revenue, cosmetic product sales and any in-house pathology or laboratory, and at what percentage. In private dermatology these components can exceed the medical professional fee; in an employed model they usually accrue to the employer. Compare offers on total structure rather than base.

Restrictive covenant radius and duration, which is unusually consequential because dermatology practices are geographically dense, malpractice with tail, the partnership pathway and buy-in in a private group or the private-equity structure if applicable, clinic template and patient volume expectation, surgical and cosmetic training support, and advanced practice provider supervision responsibilities and whether they are compensated.